Read by QxMD icon Read


Thomas Brun, Jean-Marc Bachaud, Pierre Graff-Cailleaud, Bernard Malavaud, Daniel Portalez, Christian Popotte, Richard Aziza, Amélie Lusque, Thomas Filleron, Soléakhéna Ken
PURPOSE: To present the feasibility study of optimal dose coverage in ultra-focal brachytherapy (UFB) with multiparametric MRI for low- and intermediate-risk prostate cancer. METHODS AND MATERIALS: UFB provisional dose plans for small target volumes (<7 cc) were calculated on a prostate training phantom to optimize the seeds number and strength. Clinical UFB consisted in a contour-based nonrigid registration (MRI/Ultrasound) to implant a fiducial marker at the location of the tumor focus...
March 7, 2018: Brachytherapy
Joseph M DeCunha, Shirin A Enger
PURPOSE: Renewed interest is being expressed in intravascular brachytherapy (IVBT). A number of unresolved issues exist in the discipline. Providing a homogeneous and adequate dose to the target remains difficult in IVBT. The guidewire that delivers the device to the target, arterial plaques, and stent struts are all known to reduce the dose delivered to target. The viability and efficacy of a proposed IVBT delivery system designed to resolve the issue of guidewire attenuation is evaluated and compared to that of a popular and commercially available IVBT device...
March 5, 2018: Brachytherapy
Sunil W Dutta, Kristine Bauer-Nilsen, Jason C Sanders, Daniel M Trifiletti, Bruce Libby, Donna H Lash, Melody Lain, Deborah Christodoulou, Constance Hodge, Timothy N Showalter
PURPOSE: To evaluate the delivery cost of frequently used radiotherapy options offered to patients with intermediate- to high-risk prostate cancer using time-driven activity-based costing and compare the results with Medicare reimbursement and relative value units (RVUs). METHODS AND MATERIALS: Process maps were created to represent each step of prostate radiotherapy treatment at our institution. Salary data, equipment purchase costs, and consumable costs were factored into the cost analysis...
March 5, 2018: Brachytherapy
Amandeep S Taggar, Kenneth L Pitter, Gil'ad N Cohen, Mark Schattner, Hans Gerdes, Arnold J Markowitz, David Ilson, Paul Brady, John J Cuaron, Karyn A Goodman, Abraham J Wu
PURPOSE: Management of locally recurrent or persistent esophageal cancer (EC) after standard chemoradiation is challenging. This study updates our experience of treating medically inoperable EC patients with endoluminal high-dose-rate brachytherapy (EHDRBT) including the patients treated with a novel multiballoon channel centering esophageal applicator. METHODS AND MATERIALS: Thirty-three consecutive patients with early-stage primary (n = 7), posttreatment persistent (n = 7), and recurrent (n = 19) EC treated with EHDRBT at our institution were included...
February 26, 2018: Brachytherapy
Elizabeth Watt, Leigh Conroy, Michael Peacock, Michael Roumeliotis, Amy Frederick, Siraj Husain, Tyler Meyer
PURPOSE: Postimplant analysis in permanent breast seed implant (PBSI) is performed at inconsistent times subsequent to seed implantation across cancer centers, creating challenges in the interpretation of dosimetric data and ultimately the correlation with clinical outcomes. The purpose of this study is to determine the most appropriate time postimplant to perform this analysis. METHODS AND MATERIALS: Nine patients treated at our institution with PBSI were included in this analysis...
February 26, 2018: Brachytherapy
Carla Freiberger, Vanessa Berneking, Thomas-Alexander Vögeli, Ruth Kirschner-Hermanns, Michael J Eble, Michael Pinkawa
PURPOSE: The aim of this study was to evaluate quality-of-life changes up to 10 years following three different radiotherapy concepts. METHODS AND MATERIALS: In the years 2000-2003, 295 patients were treated with external beam radiotherapy (EBRT; n = 135; 70.2 Gy in 1.8 Gy fractions), low-dose-rate brachytherapy (LDR-BT with I-125; n = 94; 145 Gy), and high-dose-rate brachytherapy (HDR-BT with Ir-192; n = 66; 18 Gy in two fractions using 4-6 needles) as a boost to EBRT (50...
February 26, 2018: Brachytherapy
Marc Gaudet, Mathieu Pharand-Charbonneau, Marie-Pierre Desrosiers, Debbie Wright, Alain Haddad
PURPOSE: To determine the acute toxicity and effect on health-related quality of life of a two-fraction regimen of high-dose-rate (HDR) prostate brachytherapy. METHODS AND MATERIALS: Patients with low- or intermediate-risk prostate cancer were treated with HDR brachytherapy as monotherapy in two implants of 13.5 Gy spaced 7-14 days apart. Patients completed International Prostate Symptom Score (IPSS) and Expanded Prostate Index Composite (EPIC) questionnaires at 1, 3, 6, 9, 12, 16, 20, and 24 months after brachytherapy...
February 23, 2018: Brachytherapy
Andres Huertas, Isabelle Dumas, Alexandre Escande, Eleonor Rivin Del Campo, Tony Felefly, Charles-Henri Canova, Anne Tailleur, Sebastien Gouy, Enrica Bentivegna, Philippe Morice, Christine Haie-Meder, Cyrus Chargari, Renaud Mazeron
PURPOSE: Primary vaginal cancer is a rare disease for which treatment has been modeled based on cervical cancer. We report our experience in the use of image-guided adaptive brachytherapy (IGABT) in this indication. METHODS AND MATERIALS: Patients treated for vaginal cancer with a combination of external beam radiation therapy and IGABT were identified through electronic search. The Groupe Européen de Curiethérapie-European Society for Radiotherapy and Oncology recommendations for cervical cancer have been extrapolated with the definition of two clinical target volumes (CTVs) corresponding to the residual disease after external beam radiation therapy (CTVBT ), assessed from clinical and imaging findings, and the so-called CTVi , comprising the CTVBT with directional margins and at least the initial disease at diagnosis...
February 6, 2018: Brachytherapy
Michael J Dohopolski, Zachary D Horne, Brian J Gebhardt, Scott M Glaser, Robert P Edwards, Joseph L Kelley, John T Comerci, Alexander B Olawaiye, Madeleine Courtney-Brooks, Jessica L Berger, Paniti Sukumvanich, Sushil Beriwal
PURPOSE: Vaginal brachytherapy (VBT) alone has been shown to be a viable adjuvant treatment strategy for most patients with Stage I endometrioid endometrial cancer. We sought to examine our institutional data following practice pattern changes resulting from the publications of GOG-99 and PORTEC-2. METHODS AND MATERIALS: We retrospectively analyzed women who underwent adjuvant VBT after surgical staging for Stage 1 endometrioid endometrial cancer at our institution from 2007 to 2014...
February 6, 2018: Brachytherapy
Sophie Otter, Amanda Coates, Adrian Franklin, Melanie Cunningham, Alexandra Stewart
PURPOSE: Image-guided brachytherapy (IGBT) is an essential component of the treatment of locally advanced cervical cancer. Interstitial (IS) catheters are being increasingly used for bulkier tumors. We have retrospectively assessed the dosimetric impact of IS catheters. METHODS AND MATERIALS: All patients who received IGBT for cervical cancer between August 2014 and February 2017 were identified. Clinical and dosimetric data were collected. Patients were grouped into the intracavitary (IC) cohort or the IC and IS implant (IC/IS) cohort...
February 6, 2018: Brachytherapy
Nobumichi Tanaka, Kazumasa Torimoto, Isao Asakawa, Makito Miyake, Satoshi Anai, Yasushi Nakai, Tomomi Fujii, Masatoshi Hasegawa, Kiyohide Fujimoto
PURPOSE: To evaluate the add-on efficacy of a cyclooxygenase (COX)-2 inhibitor on the chronological changes in urinary function in patients who underwent low-dose-rate prostate brachytherapy. METHODS AND MATERIALS: A total of 310 patients with prostate cancer who underwent low-dose-rate-brachytherapy were enrolled. Patients were randomized and allocated to the monotherapy group (tamsulosin alone: 0.2 mg/d) and the combination group (tamsulosin 0.2 mg/d plus celecoxib: 200 mg/d)...
February 2, 2018: Brachytherapy
M A Korzeniowski, J M Crook, D Bowes, M Gaztañaga, A Ots, J Jazwal, J Rose, A Tétreault-Laflamme, L Pilote, R Halperin, D Kim, D Petrik, C Araujo, F Bachand
PURPOSE: The purpose of this study was to determine the efficacy of 8 weeks of degarelix for prostate downsizing before interstitial brachytherapy. We also report associated toxicity and the time course of endocrine recovery over the following 12 months. METHODS AND MATERIALS: Fifty patients were accrued to an open-label Phase II clinical trial ( ID NCT01446991). Baseline prostate transrectal ultrasound (TRUS) was performed on all patients followed by degarelix administration and a repeat TRUS at Week 8...
February 2, 2018: Brachytherapy
David Olek, Moataz N El-Ghamry, Niloyjyoti Deb, Nitika Thawani, Courtney Shaver, Subhakar Mutyala
PURPOSE: Nonmelanoma skin cancer is the most commonly diagnosed malignancy in the United States. A modern version of surface brachytherapy, "topographic applicator brachytherapy" (TAB), can be used to treat early-stage nonmelanoma skin cancer (ES-NMSC). The purpose of this study was to evaluate the acute toxicity, chronic toxicity, and recurrence rates of patients with ES-NMSC treated with TAB. METHODS AND MATERIALS: From 2010 to 2013, 172 patients with 273 ES-NMSC tumors were consecutively treated with TAB...
February 1, 2018: Brachytherapy
Michael Roumeliotis, Brock Yates, Elizabeth Watt, Amy Frederick, Tyler Meyer
PURPOSE: Permanent breast seed implant (PBSI) is a developing brachytherapy technique for the treatment of early-stage breast cancer. In current practice, PBSI uses manual planning strategies to generate clinical treatment plans. In this work, a simulated annealing-based algorithm is developed to demonstrate the first application of inverse optimization for PBSI. METHODS AND MATERIALS: Target, skin, and chest wall muscle contours, exported from a treatment planning system in digital imaging and communications in medicine format, are used as inputs...
January 30, 2018: Brachytherapy
O A Awunor
PURPOSE: The determination of source positions before treatment is an essential part of the quality assurance (QA) associated with high dose rate brachytherapy treatments. The purpose of this study was to design and commission a tool to allow the quantification of source positions across multiple transfer tube types. METHODS AND MATERIALS: A bespoke flexi-adapter jig, three transfer tube adapters, and a film piercing pointer were designed and built for source position QA across three transfer tube types-the standard, 6 French, and gynae transfer tubes...
January 15, 2018: Brachytherapy
Eric Poulin, Karim Boudam, Csaba Pinter, Samuel Kadoury, Andras Lasso, Gabor Fichtinger, Cynthia Ménard
PURPOSE: The objective of this study was to develop and validate an open-source module for MRI to transrectal ultrasound (TRUS) registration to support tumor-targeted prostate brachytherapy. METHODS AND MATERIALS: In this study, 15 patients with prostate cancer lesions visible on multiparametric MRI were selected for the validation. T2-weighted images with 1-mm isotropic voxel size and diffusion weighted images were acquired on a 1.5T Siemens imager. Three-dimensional (3D) TRUS images with 0...
January 10, 2018: Brachytherapy
Amishi Bajaj, Grant Harmon, John Weaver, Brendan Martin, Michael Mysz, Murat Surucu, John C Roeske, Andre A Konski, William Small, Matthew M Harkenrider
PURPOSE: While some institutions deliver multiple fractions per implant for MRI-based planning, it is common for only one fraction to be delivered per implant with CT-based cervical brachytherapy. The purpose of this study was to compare physician costs, hospital costs, and overall costs for cervical cancer patients treated with either CT-based or MRI-based high-dose-rate (HDR) cervical brachytherapy to determine if MRI-based brachytherapy as described can be financially feasible. METHODS AND MATERIALS: We identified 40 consecutive patients treated with curative intent cervical brachytherapy...
January 10, 2018: Brachytherapy
Christina Hunter Chapman, Daniel Polan, Karen Vineberg, Shruti Jolly, Katherine E Maturen, Kristy K Brock, Joann I Prisciandaro
PURPOSE: To study the dosimetric impact of deformable image registration-based contour propagation on MRI-based cervical cancer brachytherapy planning. METHODS AND MATERIALS: High-risk clinical target volume (HRCTV) and organ-at-risk (OAR) contours were delineated on MR images of 10 patients who underwent ring and tandem brachytherapy. A second set of contours were propagated using a commercially available deformable registration algorithm. "Manual-contour" and "propagated-contour" plans were optimized to achieve a maximum dose to the most minimally exposed 90% of the volume (D90) (%) of 6 Gy/fraction, respecting minimum dose to the most exposed 2cc of the volume (D2cc) OAR constraints of 5...
January 10, 2018: Brachytherapy
Kamyar Mansori, Erfan Ayubi, Saeid Safiri
No abstract text is available yet for this article.
January 10, 2018: Brachytherapy
Daniel Taussky, Stéphane Bedwani, Nissan Meissner, Jean-Paul Bahary, Carole Lambert, Maroie Barkati, Marie-Claude Beauchemin, Cynthia Ménard, Guila Delouya
PURPOSE: The aim of this study was to compare early prostate-specific antigen (PSA) decline patterns and PSA nadirs between low-dose-rate seed prostate brachytherapy (LDR-PB) and different fractionations of external beam radiotherapy (EBRT) and their predictive importance for biochemical failure (bF). METHODS AND MATERIALS: Patients with D'Amico low- or intermediate-risk prostate cancer who underwent a single-modality treatment without androgen deprivation were included in this study...
January 3, 2018: Brachytherapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"